Keyphrases
Administrative Support
24%
Antipsychotic Efficacy
33%
Antipsychotics
24%
Biased Agonist
24%
Board Meetings
33%
Canonical Wnt Signaling
24%
Chapel Hill
50%
Chemical Probes
24%
Clinical Trials
24%
CNS Drug Discovery
100%
D2 Dopamine Receptor
33%
D2 Receptor Ligands
33%
Dopamine Agonist
24%
Dopamine D2 Receptor (DRD2)
33%
Drug Screening
24%
Duke University
24%
Full Agonist
24%
Functional Selectivity
100%
In Vitro Profiling
33%
In Vitro Screening
33%
In Vitro Testing
33%
In Vivo Validation
33%
Medical School
24%
National Institute of Mental Health
24%
Novel Animal Model
24%
Novel Treatments
24%
Partial Agonist
24%
Periodic Feedback
33%
Pfizer
33%
Related Disorders
50%
Schizophrenia Symptoms
66%
Schizophrenia Treatment
24%
Scientific Advisory Board
33%
Screening Program
24%
Signaling Bias
33%
Signaling Pathway
50%
Symptomatology
24%
Three-core
24%
University of North Carolina
50%
β-arrestin
24%
Medicine and Dentistry
Beta Arrestin
50%
Clinical Trial
37%
Disease
75%
Dopamine 2 Receptor Stimulating Agent
50%
Dopamine Receptor D2
50%
Drug Screening
37%
In Vitro
37%
In Vitro Screening
50%
Mental Health
37%
Partial Agonist
50%
Psychoactive Drug
37%
Screening
37%
Side Effect
37%
Signal Transduction
75%
Symptomatology
50%
Treatment of Schizophrenia
50%
Typical Antipsychotic
50%
Pharmacology, Toxicology and Pharmaceutical Science
Antipsychotic
50%
Beta Arrestin
24%
Clinical Trial
24%
Disease
50%
Dopamine 2 Receptor Stimulating Agent
33%
Dopamine Receptor D2
33%
Drug Discovery
75%
Drug Screening
24%
Functional Selectivity
100%
In Vitro Screening
33%
Partial Agonist
33%
Psychotropic Agent
24%
Side Effect
24%
Symptomatology
33%
Typical Antipsychotic
24%